Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2019 Jan 28;127(5):303–315. doi: 10.1111/apm.12920

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2019 The Authors. APMIS published by John Wiley & Sons Ltd on behalf of Scandinavian Societies for Medical Microbiology and Pathology

This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

PMC Copyright notice

Precision diagnostic workflow for breast cancer patients; Once a diagnosis of breast cancer has been verified from core‐needle biopsy, a germline analysis by whole‐genome sequencing (WGS) is initiated from whole‐blood (WH). Initially, genetic status of the major predisposing genes should be ready in time for planning of risk reducing surgery. Based on DNA and RNA from the surgical specimen, a full somatic profile and subtype is generated and finalized for multidisciplinary team (MDT) including; HRD‐status and mutation burden from DNA analyzed by WGS (PARPi or immunotherapy) as well as potential actionable targets from high‐coverage NGS‐panel; Molecular subtype, receptor status and proliferative index from RNA based on RNA‐sequencing. Histopathology includes immunohistochemical type, morphological characteristics and receptor status.